Table 1 Annual changes in RA patient numbers and the therapeutic agents used in our department
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Total | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | 645 | 766 | 811 | 871 | 964 | 1011 | 924 | 1064 | 1117 | 1126 | 9299 | |
< 60 | 194 | 222 | 220 | 223 | 276 | 284 | 238 | 274 | 260 | 268 | 2459 | |
60–69 | 223 | 257 | 269 | 274 | 275 | 281 | 240 | 278 | 264 | 258 | 2619 | |
70–79 | 176 | 216 | 232 | 263 | 291 | 313 | 314 | 348 | 398 | 406 | 2957 | |
≥ 80 | 52 | 71 | 90 | 111 | 122 | 133 | 132 | 164 | 195 | 194 | 1264 | |
Average age (s.d.) | 63.9 (12.5) | 64.2 (12.7) | 64.7 (13.1) | 63.8 (13.2) | 65.3 (13.7) | 65.7 (13.7) | 66.8 (13.0) | 66.7 (13.7) | 68.0 (13.2) | 67.7 (13.7) | 66.0 (13.4) | |
Female (%) | 499 (77.4) | 592 (77.3) | 624 (76.9) | 661 (75.9) | 734 (75.8) | 769 (76.0) | 712 (77.2) | 813 (76.4) | 854 (76.5) | 871 (77.4) | 7129 (76.7) | |
Duration, months (s.d.) | 110 (108) | 111 (110) | 117 (114) | 129 (118) | 116 (110) | 120 (112) | 132 (124) | 126 (128) | 122 (113) | 117 (113) | 120 (113) | |
MTX dose (mg/w) | 7.15 (3.88) | 7.44 (4.11) | 7.49 (4.12) | 7.65 (4.19) | 7.69 (4.23) | 7.70 (4.25) | 7.76 (4.61) | 7.71 (4.26) | 7.6 (4.22) | 7.62 (4.20) | 7.60 (4.23) | |
Use (%) | 437 (67.8) | 501 (65.4) | 523 (64.4) | 568 (65.2) | 608 (63.1) | 644 (63.7) | 555 (60.1) | 585 (55.0) | 610 (54.6) | 618 (54.9) | 5649 (60.6) | |
Use/dose | < 60 | 71.6/7.89 | 73.0/8.15 | 68.4/8.47 | 71.3/8.45 | 66.3/8.58 | 73.2/8.42 | 71.8/8.48 | 70.1/8.52 | 68.8/8.39 | 64.6/8.29 | 69.8/8.38 |
(%/mg/w) | 60–69 | 68.6/7.26 | 68.1/7.57 | 67.6/7.62 | 70.1/8.02 | 68.4/8.10 | 68.3/7.98 | 65.8/8.05 | 62.2/8.02 | 61.4/8.02 | 67.8/7.95 | 66.7/7.87 |
70–79 | 65.3/6.55 | 58.8/6.90 | 62.9/6.85 | 61.6/7.03 | 60.5/7.01 | 58.5/7.30 | 56.5/7.25 | 44.8/7/14 | 52.8/7.07 | 52.7/7.21 | 57.1/7.06 | |
≥ 80 | 57.7/5.32 | 52.1/5.59 | 47.8/5.67 | 49.5/5.85 | 50.0/5.77 | 45.9/5.54 | 37.9/6.18 | 39.0/6.02 | 30.3/5.95 | 28.9/6.05 | 40.5/5.83 | |
PRED dose | 4.20 (2.38) | 4.06 (2.35) | 4.49 (2.71) | 4.72 (2.70) | 4.56 (2.62) | 4.80 (2.78) | 4.79 (2.81) | 4.48 (2.64) | 4.48 (2.65) | 4.62 (2.85) | 4.53 (2.67) | |
use (%) | 199 (30.8) | 220 (28.7) | 236 (29.0) | 249 (28.6) | 274 (28.4) | 287 (28.4) | 260 (28.1) | 263 (24.7) | 337 (30.2) | 338 (30.0) | 2663 (28.6) | |
bDMARDs (%) | 178 (27.6) | 170 (22.2) | 200 (24.7) | 193 (22.2) | 199 (20.6) | 289 (28.6) | 212 (22.9) | 256 (24.1) | 256 (22.9) | 271 (24.1) | 2224 (23.9) | |
TNFi (%) | 75.3 | 68.2 | 70.0 | 67.9 | 65.3 | 69.9 | 50.9 | 52.0 | 48.8 | 49.8 | 60.9 | |
IL6Ri (%) | 18.5 | 21.8 | 20.5 | 23.3 | 26.1 | 19.0 | 30.2 | 26.6 | 30.5 | 32.5 | 25.2 | |
Abatacept (%) | 6.2 | 10.0 | 9.5 | 8.8 | 8.5 | 11.1 | 18.9 | 21.5 | 20.7 | 17.7 | 13.9 | |
tsDMARDs (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 6 (0.6) | 11 (1.1) | 18 (1.9) | 29 (2.7) | 46 (4.1) | 55 (4.9) | 166 (1.8) | |